(Total Views: 424)
Posted On: 07/07/2025 3:27:00 AM
Post# of 155096
December 7, 2022 R&D Update:
Pg. 98
Refocusing Pipeline on High Value Opportunities
Under Oncology:
*Seek co-development partners
*Studying immunologically colder tumors
__
2022 presentation is the only cold tumor mention.
__
For years Cytodyn mentioned ICI's in the just a context of common combo testing
One of the past mTNBC trials, is the only source that measured Leronlimab dose escalation & PD-L1.
Could say highly probable upregulating was indeed, just being constructed around 3rd qtr of 2024 & why we created the Oncology Advisory Panel
Also hence 2nd MOA press release 2 days before May 15th ESMO poster
All of our 3rd-party trials on hold, are too, cold tumors
All should now be very close to moving frwd....
Pg. 98
Refocusing Pipeline on High Value Opportunities
Under Oncology:
*Seek co-development partners
*Studying immunologically colder tumors
__
2022 presentation is the only cold tumor mention.
__
For years Cytodyn mentioned ICI's in the just a context of common combo testing
One of the past mTNBC trials, is the only source that measured Leronlimab dose escalation & PD-L1.
Could say highly probable upregulating was indeed, just being constructed around 3rd qtr of 2024 & why we created the Oncology Advisory Panel
Also hence 2nd MOA press release 2 days before May 15th ESMO poster
All of our 3rd-party trials on hold, are too, cold tumors
All should now be very close to moving frwd....
(1)
(0)
